Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Congenital Abnormalities 1

Interventions

Cytarabine 8Mitoxantrone 5Peripheral Blood Stem Cell Transplantation 3Idarubicin 3Filgrastim 3Etoposide 3Busulfan 3fludarabine phosphate 2Vorinostat 2Tacrolimus 2Methotrexate 2Decitabine 2Cyclophosphamide 2Bortezomib 2tanespimycin 1ixazomib 1entinostat 1eltrombopag 1choline magnesium trisalicylate 1alvocidib 1Sorafenib 1Proteasome Inhibitors 1Pravastatin 1Mycophenolic Acid 1Metformin 1Lenalidomide 1Immunologic Techniques 1Homoharringtonine 1Granulocyte Colony-Stimulating Factor 1Gemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Leukemia, Myelomonocytic, Acute × Proteasome Inhibitors × Clear all
NCT02030405 2019-04-05

Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Stanford University

Phase 2 Terminated
4 enrolled 10 charts
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡